CTI BioPharma (CTIC) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Financial Fact:
Selling, general and administrative: 15.22M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Selling, general and administrative: 15.22M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
CTI BioPharma (NASDAQ: CTIC) reported Q3 EPS of ($0.19), $0.07 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $1 million versus the consensus estimate of $16.3 million.
For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
